HEMOSENSE INC Form 8-K April 05, 2006

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

March 30, 2006

**Date of Report (date of earliest event reported)** 

HEMOSENSE, INC.

(Exact name of Registrant as specified in its charter)

**Delaware** (State or other jurisdiction of

incorporation or organization)

001-32541 (Commission File Number)

651 River Oaks Parkway

San Jose, California 95134

(Address of principal executive offices)

(408) 719-1393

(Registrant s telephone number, including area code)

77-0452938 (I.R.S. Employer

**Identification Number)** 

#### N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 1.01. Entry into a Material Definitive Agreement.

On March 30, 2006 HemoSense, Inc., a Delaware corporation ( HemoSense ), entered into a Packaging Agreement (the Agreement ) with J-PAC, LLC, a Delaware limited liability company ( J-PAC ). Pursuant to the terms of this Agreement, J-PAC will provide pouching, packaging, and shipping services to support HemoSense s production of INRatio Test Strips in support of the INRatio PT/INR Monitoring System product line.

#### Item 9.01. Financial Statements and Exhibits.

#### (d) Exhibits.

Exhibit No. Description

99.1 Press Release of HemoSense, Inc. dated April 5, 2006

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### HEMOSENSE, INC.

Date: April 5, 2006 By: /s/ James D. Merselis

President and Chief Executive Officer

#### EXHIBIT INDEX

Exhibit No.

**Description**Press Release of HemoSense, Inc. dated April 5, 2006 99.1